Bibliography
- NNIS: National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32(8):470-85
- McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006;12(11):1715-23
- Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006;144(5):368-70
- Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355(7):666-74
- King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144(5):309-17
- Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42(5):647-56
- Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998;42(5):1303-4
- Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1(8575-6):57-8
- Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40(1):135-6
- Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7(2):327-32
- Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1(3):147-55
- CDC: Vancomycin-resistant Staphylococcus aureus – Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51(40):902
- Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus – an antibiotic enters obsolescence. Clin Infect Dis 2007;44(12):1543-8
- Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44(11):3883-6
- Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42(6):2398-402
- Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166(19):2138-44
- Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82(5):333-9
- Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44(2):190-6
- Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004;38(9):1279-86
- Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49(6):2260-6
- Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12):1673-81
- Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
- Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25(3):980-92
- Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32(3):402-12
- Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002;35(8):1018-20
- Ben Mansour EH, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003;22(6):372-3
- Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191(12):2149-52
- Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355(7):653-65
- Geraci JE, Heilman FR, Nichols DR, et al. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proc Staff Meet Mayo Clin 1956;31(21):564-82
- Bardone MR, Paternoster M, Coronelli C. Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. II. Extraction and chemical characterization. J Antibiot (Tokyo) 1978;31(3):170-7
- Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol 2004;4(5):471-8
- Perkins HR, Nieto M. The chemical basis for the action of the vancomycin group of antibiotics. Ann NY Acad Sci 1974;235(0):348-63
- Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004;57(5):326-36
- Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(3):1127-34
- Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett 2003;13(23):4165-8
- Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(8):2538-44
- Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(11):3602-4
- King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004;53(5):797-803
- Draghi DC, Benton BM, Cohen MA, et al. Baseline anti-staphylococcal profile of telavancin: results of the 2005 USA Surveillance Initiative. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27 – 30 September 2006; San Francisco, CA
- Draghi D, Benton B, Jones M, et al. Europe surveillance initiative profiling the anti-staphylococcal activity of telavancin by specimen source from 2004 to 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases; 31 March – 3 April 2007; Munich, Germany
- Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(2):338-43
- Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2007;60(2):406-9
- Draghi D, Benton B, Jones M, et al. Europe surveillance initiative profiling the activity of telavancin against streptococci by specimen source from 2004 to 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases; 31 March – 3 April 2007; Munich, Germany
- Thornsberry C, Draghi DC, Benton BM, et al. Baseline profile of telavancin activity against streptococci: results of the USA Surveillance Initiative. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27 – 30 September 2006; San Francisco, CA
- Sahm D, Draghi D, Benton B, et al. Europe surveillance initiative profiling the anti-enterococcal activity of telavancin by specimen source from 2004 to 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases; 31 March – 3 April 2007; Munich, Germany
- Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004;48(6):2149-52
- Kaniga K, Blosser RS, Karlowsky JA, Sahm DF. In vitro activity of telavancin (TD-6424) against Bacillus anthracis. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 30 October – 2 November 2004; Washington, DC
- Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(6):1177-84
- Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005;56(2):337-43
- Sahm DF, Benton BM, Cohen MA, et al. Telavancin demonstrates a low potential for in vitro selection of resistance among key target Gram-positive species. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27 – 30 September 2006; San Francisco, CA
- Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 2005;40(11):1601-7
- Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50(3):862-7
- Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004;48(8):3043-50
- Reyes N, Skinner R, Benton BM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(2):462-5
- Madrigal AG, Basuino L, Chambers HF. Efficacy of Ttlavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(8):3163-5
- Miro JM, Garcia-De-La-Maria C, Armero Y, et al. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2007;51(7):2373-7
- Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(10):4344-6
- Stucki A, Gerber P, Acosta F, et al. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006;50(2):770-3
- Odenholt I, Lowdin E, Cars O. The pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus in the presence of human albumin or serum, and in an in vitro kinetic model. Antimicrob Agents Chemother 2007;51(9):3311-6
- Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49(1):195-201
- Sun HK, Duchin K, Nightingale CH, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006;50(2):788-90
- Wong SL, Shaw JP, Gotfried MH, et al. Compartmental analysis of telavancin penetration into epithelial lining fluid and alveolar macrophages. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27 – 30 September 2006; San Francisco, CA
- Gotfried M, Duchin K, Shaw J, et al. Telavancin (TLV) penetrates well into human pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) and is unaffected by pulmonary surfactant. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16 – 19 December 2005; Washington, DC
- Patel JH, Grio MC, Churchwell MD, et al. Telavancin transmembrane clearance during in vitro continuous venovenous hemofiltration [abstract p1538]. 16th European Congress of Clinical Microbiology and Infectious Diseases; 1 – 4 April 2006; Nice, France
- Wong SL, Shaw JP, Barriere SL, et al. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27 – 30 September 2006; San Francisco, CA
- Goldberg M, Ballow C, Wong S, et al. Phase 1, double-blind, crossover study to evaluate the interaction of telavancin and midazolam in healthy subjects. 42nd Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP); 2 – 6 December 2007; Las Vegas, NV
- Sahm DF, Benton BM, Cohen MA, et al. Interaction of telavancin and other antimicrobial agents tested against key Gram-positive species. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27 – 30 September 2006; San Francisco, CA
- Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
- Corey G, Stryjewski M, Fowler VJ, et al. The ATLAS studies: double-blind, randomised, active controlled, multinational phase 3 trials comparing telavancin with vancomycin for the treatment of complicated skin and skin structure infections. Clin Microbiol Infect 2007;13(Suppl 1):P844
- Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004;44(7):689-95
- Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-22
- Barriere S, Shaw JP, Seroogy J, et al. Pharmacokinetics (PK) & safety of a new antibacterial, TD-6424 (TD), in healthy subjects. [abstract A-20]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 14 – 17 September 2003; Chicago, Illinois
- Available from: http://www.clinicaltrials.gov [Accessed 7 July 2008]
- Draghi DC, Benton BM, Cohen MA, et al. In vitro activity of telavancin against enterococci: results of the 2004 – 2005 US Surveillance Initiative. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27 – 30 September 2006; San Francisco, CA